Biological
Aglatimagene besadenovec clinical trials
Also written AdV-tk and CAN-2409.
- studies test it
- 14
- open now
- 2
- in phase 3
- 3
- first study started
- 2005
Keep track of what changes. Save the aglatimagene besadenovec studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 6
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 2
Candel Therapeutics, Inc. (12) · Huazhong University of Science and Technology (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses aglatimagene besadenovec is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecRecruitingPhase 2Candel Therapeutics, Inc.NCT07332000Written as aglatimagene besadenovec + valacyclovir
- Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingPhase 3Candel Therapeutics, Inc.NCT07660094Written as Aglatimagene Besadenovec
- Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerActive, not recruitingPhase 3Candel Therapeutics, Inc.NCT01436968Written as Aglatimagene besadenovec + valacyclovir
- Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Active, not recruitingPhase 2Candel Therapeutics, Inc.NCT02768363Written as aglatimagene besadenovec
- CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive, not recruitingPhase 2Candel Therapeutics, Inc.NCT04495153Written as Aglatimagene besadenovec
- Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerCompletedPhase 1Candel Therapeutics, Inc.NCT03131037Written as CAN-2409 + valacyclovir
- Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaCompletedPhase 2Candel Therapeutics, Inc.NCT00589875Written as CAN-2409
- Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaActive, not recruitingPhase 2Candel Therapeutics, Inc.NCT02446093Written as Aglatimagene besadenovec
- A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsCompletedPhase 1Candel Therapeutics, Inc.NCT00634231Written as AdV-tk
- AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)CompletedPhase 1Candel Therapeutics, Inc.NCT00638612Written as AdV-tk
- Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasCompletedPhase 1Candel Therapeutics, Inc.NCT00751270Written as AdV-tk
- Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionCompletedPhase 1Candel Therapeutics, Inc.NCT01997190Written as AdV-tk + valacyclovir
- Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCStatus unknownPhase 3Huazhong University of Science and TechnologyNCT03313596Written as ADV-Tk
- Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 2Huazhong University of Science and TechnologyNCT02202564Written as ADV-TK
Given in every arm · 1 — aglatimagene besadenovec is usual care beside what is tested
Codes
What other systems call aglatimagene besadenovec · ClinicalTrials.gg INT015153
- UNII (FDA) 5Z72SSS34WAGLATIMAGENE BESADENOVECOne source FDA
- NCI Thesaurus C73996Aglatimagene BesadenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5Z72SSS34W | AGLATIMAGENE BESADENOVEC | One source FDA |
| NCI Thesaurus | C73996 | Aglatimagene Besadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.